CUBT (Curative Biotechnology) EBITDA Margin %: 0.00% (As of Mar. 2023)


What is Curative Biotechnology EBITDA Margin %?

Curative Biotechnology CUBT +17.98% EBITDA Margin % is 0.00% as of Mar. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Curative Biotechnology's EBITDA for the three months ended in Mar. 2023 was $-0.65 Mil. Curative Biotechnology's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Curative Biotechnology's EBITDA margin for the quarter that ended in Mar. 2023 was 0.00%.

Curative Biotechnology  (OTCPK:CUBT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Curative Biotechnology EBITDA Margin % Related Terms

Curative Biotechnology EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology EBITDA Margin % Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CUBT vs ORGS, SNSE, TNXP: EBITDA Margin % Comparison

For the Biotechnology subindustry, Curative Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's EBITDA Margin % falls into.


Curative Biotechnology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Curative Biotechnology's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-4.427/0
= %

Curative Biotechnology's EBITDA Margin % for the quarter that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-0.653/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Curative Biotechnology (CUBT) has a EBITDA Margin % of 0.00% as of Mar. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Curative Biotechnology and its competitors.
Is Curative Biotechnology's EBITDA Margin % too high?
Curative Biotechnology's current EBITDA Margin % is 0.00%.
How does Curative Biotechnology's EBITDA Margin % compare to ORGS and SNSE?
Curative Biotechnology's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Curative Biotechnology and its competitors. Curative Biotechnology's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current EBITDA Margin % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.